Emerging biomarkers for immune checkpoint inhibition in lung cancer

Seminars in Cancer Biology
George Cyriac, Leena Gandhi

Abstract

Immune checkpoint inhibition with anti-PD-1 therapy has been notably successful in non-small cell lung cancer (NSCLC) and changed standard practice in multiple settings. However, despite some durable benefits seen, the majority of unselected patients with NSCLC fail to respond to checkpoint inhibitors. Patient selection is crucial and will become even more important in the development of combination therapies with immune checkpoint inhibitors. PD-L1 expression by immunohistochemistry (IHC) has emerged as the most commonly used clinical biomarker of response and overall tumor mutational burden (TMB) is being explored as a clinical biomarker. However, both are hampered by being imperfect predictors of response and both can be dynamic during the course of illness. In this review, we will discuss the development of PD-L1 expression as a biomarker as well as the ongoing emergence of other genomic and proteomic markers that can help refine our use of immunotherapies to maximize benefit in the most patients.

Citations

Sep 20, 2019·Nature Protocols·Ziming DuSandro Santagata
Jun 13, 2019·Oncology Letters·Liang-Liang Cai, Jie Wang
Sep 28, 2018·Journal of Clinical Medicine·Ori Wald
Dec 5, 2019·Therapeutic Advances in Medical Oncology·Marika CinauseroAndrea Ardizzoni
Feb 23, 2020·Cancer Biomarkers : Section a of Disease Markers·Yanlu XiongYong Han
Aug 9, 2020·Cancer Management and Research·Peng SongLi Zhang
Mar 9, 2019·International Journal of Clinical Oncology·Satoru SenooKatsuyuki Kiura
Dec 24, 2018·Therapeutic Advances in Medical Oncology·Federico Pio FabrizioLucia Anna Muscarella
Sep 27, 2018·World Journal of Gastroenterology : WJG·Matthias Ocker
Oct 28, 2020·Technology in Cancer Research & Treatment·Eda G Ramirez-VallesCarlos A Alba-Fierro
Oct 17, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Lihua WangWenhui Xie
Dec 18, 2020·Frontiers in Oncology·Kamila Wojas-Krawczyk, Tomasz Kubiatowski
Nov 25, 2021·Journal of Clinical Laboratory Analysis·Fenqi Du, Yanlong Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

The Cancer Journal
Fernando C Santini, Matthew D Hellmann
Journal of the Advanced Practitioner in Oncology
Elizabeth S Waxman, Frank V Fossella
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Kazuhiko ShienIgnacio I Wistuba
© 2022 Meta ULC. All rights reserved